A step forward for LRRK2 inhibitors in Parkinson's disease

被引：11
作者：
Lewis, Patrick A. [1 ,2 ,3 ]
机构：
[1] Royal Vet Coll, London NW1 0TU, England
[2] UCL Queen Sq Inst Neurol, London WC1N 3BG, England
[3] Aligning Sci Across Parkinsons ASAP Collaborath R, Chevy Chase, MD 20815 USA
来源：
SCIENCE TRANSLATIONAL MEDICINE | 2022年 / 14卷 / 648期
关键词：
MUTATIONS;
D O I：
10.1126/scitranslmed.abq7374
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.
引用
收藏
页数：3
相关论文
共 10 条
  • [1] LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
    Baptista, Marco A. S.
    Merchant, Kalpana
    Barrett, Ted
    Bhargava, Sakshi
    Bryce, Dianne K.
    Ellis, J. Michael
    Estrada, Anthony A.
    Fell, Matthew J.
    Fiske, Brian K.
    Fuji, Reina N.
    Galatsis, Paul
    Henry, Anastasia G.
    Hill, Sue
    Hirst, Warren
    Houle, Christopher
    Kennedy, Matthew E.
    Liu, Xingrong
    Maddess, Matthew L.
    Markgraf, Carrie
    Mei, Hong
    Meier, William A.
    Needle, Elie
    Ploch, Stephen
    Royer, Christopher
    Rudolph, Karin
    Sharma, Alok K.
    Stepan, Antonia
    Steyn, Stefan
    Trost, Craig
    Yin, Zhizhang
    Yu, Hongshi
    Wang, Xiang
    Sherer, Todd B.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (540)
  • [2] The genetic architecture of Parkinson's disease
    Blauwendraat, Cornelis
    Nalls, Mike A.
    Singleton, Andrew B.
    [J]. LANCET NEUROLOGY, 2020, 19 (02) : 170 - 178
  • [3] Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease
    Blauwendraat, Cornelis
    Reed, Xylena
    Kia, Demis A.
    Gan-Or, Ziv
    Lesage, Suzanne
    Pihistrom, Lasse
    Guerreiro, Rita
    Gibbs, J. Raphael
    Sabir, Marya
    Ahmed, Sarah
    Ding, Jinhui
    Alcalay, Roy N.
    Hassin-Baer, Sharon
    Pittman, Alan M.
    Brooks, Janet
    Edsall, Connor
    Hernandez, Dena G.
    Chung, Sun Ju
    Goldwurm, Stefano
    Toft, Mathias
    Schulte, Claudia
    Bras, Jose
    Wood, Nicholas W.
    Brice, Alexis
    Morris, Huw R.
    Scholz, Sonja W.
    Nalls, Mike A.
    Singleton, Andrew B.
    Cookson, Mark R.
    [J]. JAMA NEUROLOGY, 2018, 75 (11) : 1416 - 1422
  • [4] Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
    Greggio, Elisa
    Jain, Shushant
    Kingsbury, Ann
    Bandopadhyay, Rina
    Lewis, Patrick
    Kaganovich, Alice
    van der Brug, Marcel P.
    Beilina, Alexandra
    Blackinton, Jeff
    Thomas, Kelly Jean
    Ahmad, Rill
    Miller, David W.
    Kesavapany, Sashi
    Singleton, Andrew
    Lees, Andrew
    Harvey, Robert J.
    Harvey, Kirsten
    Cookson, Mark R.
    [J]. NEUROBIOLOGY OF DISEASE, 2006, 23 (02) : 329 - 341
  • [5] Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study
    Jabbari, Edwin
    Koga, Shunsuke
    Valentino, Rebecca R.
    Reynolds, Regina H.
    Ferrari, Raffaele
    Tan, Manuela M. X.
    Rowe, James B.
    Dafgard, Clifton L.
    Scholz, Sonja W.
    Dickson, Dennis W.
    Warner, Thomas T.
    Revesz, Tanias
    Hoeglinger, Gunter U.
    Ross, Owen A.
    Ryten, Mina
    Hardy, John
    Shoai, Maryam
    Morris, Huw R.
    [J]. LANCET NEUROLOGY, 2021, 20 (02) : 107 - 116
  • [6] Jennings D., 2022, SCI TRANSL MED, V14
  • [7] Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
    Paisán-Ruíz, C
    Jain, S
    Evans, EW
    Gilks, WP
    Simón, J
    van der Brug, M
    de Munain, AL
    Aparicio, S
    Gil, AM
    Khan, N
    Johnson, J
    Martinez, JR
    Nicholl, D
    Carrera, IM
    Pena, AS
    de Silva, R
    Lees, A
    Martí-Massó, JF
    Pérez-Tur, J
    Wood, NW
    Singleton, AB
    [J]. NEURON, 2004, 44 (04) : 595 - 600
  • [8] Kinase activity of mutant LRRK2 mediates neuronal toxicity
    Smith, Wanli W.
    Pei, Zhong
    Jiang, Haibing
    Dawson, Valina L.
    Dawson, Ted M.
    Ross, Christopher A.
    [J]. NATURE NEUROSCIENCE, 2006, 9 (10) : 1231 - 1233
  • [9] LRRK2 in Parkinson disease: challenges of clinical trials
    Tolosa, Eduardo
    Vila, Miquel
    Klein, Christine
    Rascol, Olivier
    [J]. NATURE REVIEWS NEUROLOGY, 2020, 16 (02) : 97 - 107
  • [10] Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology
    Zimprich, A
    Biskup, S
    Leitner, P
    Lichtner, P
    Farrer, M
    Lincoln, S
    Kachergus, J
    Hulihan, M
    Uitti, RJ
    Calne, DB
    Stoessl, AJ
    Pfeiffer, RF
    Patenge, N
    Carbajal, IC
    Vieregge, P
    Asmus, F
    Müller-Myhsok, B
    Dickson, DW
    Meitinger, T
    Strom, TM
    Wszolek, ZK
    Gasser, T
    [J]. NEURON, 2004, 44 (04) : 601 - 607
1